TL;DR: CSL announced on September 29, 2026 that it will work with Amazon Web Services to use AI and cloud technology across research and clinical development.
What CSL announced on September 29
Australian biotechnology firm CSL said on Tuesday, September 29, 2026 that it is collaborating with Amazon's cloud arm to harness AI and cloud technology across its research and clinical development pipeline, according to Reuters in "Australia's CSL taps Amazon's cloud unit to boost research pipeline | Reuters."
The announcement was issued from King of Prussia, Pa., on September 29, 2026, according to the CSL newsroom announcement titled "CSL and AWS collaborate to advance biopharmaceutical R&D."
CSL said the collaboration will apply artificial intelligence and cloud technologies to support the company's research and clinical development, according to that CSL announcement.
The Reuters report identified the cloud partner as Amazon Web Services Inc., associated with Amazon.com Inc. and CSL Limited.
Reuters reported the announcement at 12:47 AM UTC on September 29, 2026, with an update the same day.
Reporting was credited to Aamir Shaik Khalid in Bengaluru, with editing by Subhranshu Sahu, according to the Reuters account carried by affiliated reports.
Why CSL says the AWS work matters for discovery
The collaboration supports CSL's strategic R&D priorities by helping scientists connect and analyze scientific data, according to the CSL announcement.
CSL said the work is intended to help identify potential targets earlier, accelerate timelines, and assess external opportunities more efficiently, according to the same CSL announcement.
The partnership with Amazon Web Services will enable CSL's scientists to analyse complex scientific data and identify potential drug targets earlier in the discovery process, helping to accelerate research and shorten development timelines, the company said, according to Reuters.
CSL said it aims to link laboratory and computational work more closely, according to Reuters.
That closer link is intended to enable experimental findings to inform research models and decisions faster, according to Reuters and the CSL announcement.
In the CSL announcement, the company said experimental findings informing research models and decisions faster would connect laboratory work with computational analysis.
CSL described the effort as part of a broader effort to use technology responsibly to strengthen and accelerate scientific discovery and decision-making, according to the CSL announcement.
The company also said the broader technology effort is intended to streamline development and help advance promising therapies for patients faster, according to that announcement.
What will change in clinical development
In clinical development, CSL is working with AWS to reduce manual effort in areas including protocol authoring, clinical data handling and regulatory submissions, according to the CSL announcement.
On the clinical front, CSL said it will also use AWS's cloud and AI tools to reduce manual workloads in protocol drafting, data management, and submission processes, according to Reuters.
CSL said the clinical-development work will maintain appropriate data governance, traceability and inspection readiness, according to the CSL announcement.
The stated objective is to carry a program from design through submission with more speed and confidence, according to the statement from CSL executive Arturo Morales, Ph.D., quoted in the CSL announcement.
Morales is Head of Technology Enabled Sciences at CSL, according to that announcement.
The CSL announcement quoted Morales saying the company is building a research and development environment where discovery moves faster.
The same quoted statement said CSL's mission is to develop therapies that change patients' lives and that the company wants to give scientists and clinical teams the best tools to do their work.
How CSL and AWS divide responsibilities
CSL sets the scientific priorities, standards and portfolio strategy for the collaboration, according to the CSL announcement.
CSL also draws on a broader ecosystem of technology partners to deliver it, according to that announcement.
AWS is the principal AI and cloud provider in this effort, according to the CSL announcement.
AWS contributes cloud infrastructure, innovative tooling, technical expertise, and AI capabilities through services such as Amazon Bedrock to improve efficiencies across CSL's R&D processes, according to that announcement.
AWS is also working alongside CSL to build AI fluency across CSL's R&D workforce, according to the CSL announcement.
The Reuters report described AWS as Seattle-based, and described CSL as an Australian biotechnology firm.
What CSL is as a company
CSL is listed as ASX:CSL and USOTC:CSLLY, according to the CSL announcement.
The company describes itself as a leading global biopharma company with a dynamic portfolio of lifesaving medicines, according to that announcement.
That portfolio includes medicines that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology, according to the announcement.
CSL traces its start to 1916 and says it has been driven by a promise to save lives using the latest technologies, according to the announcement.
Today, CSL — including its three businesses, CSL Behring, CSL Seqirus and CSL Vifor — provides lifesaving products to patients in more than 100 countries and employs more than 29,000 people, according to the announcement.
The company said its combination of commercial strength, R&D focus and operational excellence enables it to identify, develop and deliver innovations, according to the announcement.
For more information about CSL, the company pointed readers to https://www.csl.com/, according to the announcement.
The listed CSL media contact was Jasmin Joller at [email protected], according to the announcement.
Market and policy context reported alongside the deal
Shares of CSL were largely unchanged at A$181.9, as of 0023 GMT on September 29, according to Reuters.
In mid-August, CSL posted better-than-expected annual underlying earnings and forecast growth in 2027 on the back of its core plasma division, according to Reuters.
The partnership with Seattle-based AWS comes after U.S. President Donald Trump announced a new round of drug-pricing agreements with international pharmaceutical companies, including CSL, in early September, according to Reuters.
Reuters did not state a transaction value, contract length, or product approval outcome tied to the AWS collaboration.
The CSL announcement did not state a transaction value, contract length, or product approval outcome tied to the AWS collaboration.
Both accounts described the arrangement as a collaboration to support research and clinical development, not as a completed drug approval or product release.
What to watch next
The practical test described by CSL is whether connected scientific data and earlier target identification shorten research timelines, according to the CSL announcement and Reuters.
A second test is whether reduced manual effort in protocol authoring, clinical data handling and regulatory submissions changes development speed while maintaining governance, traceability and inspection readiness, according to the CSL announcement.
A third test is whether laboratory findings inform computational models and decisions faster under the linked lab-computational approach, according to both accounts.
A fourth area to watch is AI fluency across CSL's R&D workforce, because AWS is working alongside CSL on that training element, according to the CSL announcement.
For readers, the distinction is that September 29 brought an announced collaboration with stated R&D process goals, not a reported research finding or regulatory submission result, according to Reuters and the CSL announcement.